STAT3 Signaling in Breast Cancer: Multicellular Actions and Therapeutic Potential
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)-6 family cytokines, such as IL-6 and IL-11, are defined by the shared use of the gp130 receptor for the downstream activation of STAT3 signaling and the activation of genes which contribute to the “hallmarks of cancer”, including proliferation, survival, invasion and metastasis. Increased expression of these cytokines, or the ligand-specific receptors IL-6R and IL-11RA, in breast tumors positively correlate to disease progression and poorer patient outcome. In this review, we examine evidence from pre-clinical studies that correlate enhanced IL-6 and IL-11 mediated gp130/STAT3 signaling to the progression of breast cancer. Key processes by which the IL-6 family cytokines contribute to the heterogeneous nature of breast cancer, immune evasion and metastatic potential, are discussed. We examine the latest research into the therapeutic targeting of IL-6 family cytokines that inhibit STAT3 transcriptional activity as a potential breast cancer treatment, including current clinical trials. The importance of the IL-6 family of cytokines in cellular processes that promote the development and progression of breast cancer warrants further understanding of the molecular basis for its actions to help guide the development of future therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · cited 5×
“Classical STAT3 signaling is activated by the binding of IL-6 and IL-11 to their respective cell surface receptors IL-6R and IL-11R, and the interaction of this complex to the shared cognate receptor gp130 (also known as IL-6Rβ) to activate intracellular STAT3 signaling [4,16].”
BackgroundInfluentialIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 1×
“The soluble form of gp130 (sgp130) acts as a negative regulator of trans-signaling by competing with membrane-bound gp130 to bind to the ligand–receptor complex, thus preventing the activation of intracellular STAT3 [16,23].”
BackgroundRevisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 1×
“A critical cytokine-dependent mechanism that promotes immune evasion during metastasis is transforming growth factor β (TGFβ)/IL-11 signaling axis [95,96].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Mechanisms and consequences of Jak–STAT signaling in the immune system
Villarino, A. V., Kanno, Y., & O'Shea, J. J. (2017) · Nature Immunology · doi:10.1038/ni.3691 · Cited by 1,221
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207 · cited 2×
“STAT3 is known to regulate many genes involved in immune escape and chemoresistance, such as TGF-β [48], VEGF [49], NF-κB [34], OCT-4 and cMYC [50], presenting an attractive option for dual-targeting approaches.”
BackgroundDependency of Colorectal Cancer on a TGF-β-Driven Program in Stromal Cells for Metastasis Initiation
Calon, A., Espinet, E., Palomo-Ponce, S., Tauriello, D. V. F., Iglesias, M., Céspedes, M. V., Sevillano, M., Nadal, C., Jung, P., Zhang, X. H.-F., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.013 · Cited by 1,060
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639 · cited 1×
“IL-6 is also known to promote breast cancer invasion to the bone, upregulating the chemokine receptor CXCR4 via STAT3 signaling in breast cells to promote proliferation of breast cells to the bone matrix [76].”
BackgroundInflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Yadav, A., Kumar, B., Datta, J., Teknos, T. N., & Kumar, P. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0271 · Cited by 503
Nicholson, S. E., De Souza, D., Fabri, L. J., Corbin, J., Willson, T. A., Zhang, J.-G., Silva, A., Asimakis, M., Farley, A., Nash, A. D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100135197 · Cited by 456
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
Kumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L. R., McCaffrey, J. C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.014 · Cited by 371
Walter, M., Liang, S., Ghosh, S., Hornsby, P. J., & Li, R. (2009) · Oncogene · doi:10.1038/onc.2009.130 · Cited by 312
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
Bendell, J. C., Hong, D. S., Burris, H. A., Naing, A., Jones, S. F., Falchook, G., Bricmont, P., Elekes, A., Rock, E. P., & Kurzrock, R. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2480-2 · Cited by 115
Khan, M. W., Saadalla, A., Ewida, A. H., Al-Katranji, K., Al-Saoudi, G., Giaccone, Z. T., Gounari, F., Zhang, M., Frank, D. A., & Khazaie, K. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2057-0 · Cited by 103
Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., Jin, G., Watabe, K., & Lo, H.-W. (2018) · Oncogene · doi:10.1038/s41388-018-0132-4 · Cited by 96 · cited 2×
“Co-overexpression of these proteins was also present in lymph node metastases, and patients with co-activated STAT3/GLI1 breast tumors had poor long-term survival outcomes [42,43].”
BackgroundKim, D. J., Tremblay, M. L., & DiGiovanni, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010290 · Cited by 83
Fleming, J. D., Giresi, P. G., Lindahl-Allen, M., Krall, E. B., Lieb, J. D., & Struhl, K. (2015) · Epigenetics & Chromatin · doi:10.1186/1756-8935-8-7 · Cited by 39 · cited 2×
“Utilizing genome-wide chromatin immunoprecipitation-sequencing (ChIP-seq) in the immortalized mammary epithelial cell line MCF-10A, STAT3 binding sites were found to be enriched in the promoters of genes regulating cell movement, growth proliferation and inflammation in a normal breast setting [33].”
Background
Cited by
Li, Q., Cheng, Y., Zhang, Z., Bi, Z., Ma, X., Wei, Y., & Wei, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1036 · Cited by 77
Widjaja, A. A., Viswanathan, S., Wei Ting, J. G., Tan, J., Shekeran, S. G., Carling, D., Lim, W.-W., & Cook, S. A. (2022) · iScience · doi:10.1016/j.isci.2022.104806 · Cited by 45
CD109, a master regulator of inflammatory responses
Batal, A., Garousi, S., Finnson, K. W., & Philip, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1505008 · Cited by 21
Metadata
- Authors
- To, S. Q., Dmello, R. S., Richards, A. K., Ernst, M., & Chand, A. L.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-01-15
- Volume
- 14
- Issue
- 2
- Pages
- 429
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4206091729
- Cited by
- 86
- References
- 25
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.